ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Indianapolis, IN, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Indianapolis, Indiana, United States and 51 other locations

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Indianapolis, Indiana, United States and 108 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Indianapolis, Indiana, United States and 43 other locations

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

Indianapolis, Indiana, United States and 110 other locations

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

Indianapolis, Indiana, United States and 85 other locations

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to det...

Enrolling
Acute Leukemias
Acute Lymphoblastic Leukemia
Drug: Bleximenib

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Indianapolis, Indiana, United States and 30 other locations

Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia. Using a standard 3+3 design, subjects will receive once cycle of...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Gemtuzumab Ozogamicin

Phase 1

John Quigley

Indianapolis, Indiana, United States and 3 other locations

with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comor...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Decitabine and Cedazuridine (ASTX727)
Drug: Venetoclax

Phase 1, Phase 2

Taiho Pharma
Taiho Pharma

Indianapolis, Indiana, United States and 33 other locations

with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when g...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Indianapolis, Indiana, United States and 164 other locations

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orall...

Active, not recruiting
Blastic Phase Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia
Drug: Bosutinib

Phase 1, Phase 2

Children's Oncology Group

Indianapolis, Indiana, United States and 44 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems